Cure My Disease

Don't miss your cure!

 Log in / Sign up

New cancer drug shows promise in early human trial

NCT ID NCT03573310

Completed Disease control Sponsor: Janssen Research & Development, LLC Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This early-stage trial tested a new oral drug, JNJ-64619178, in 114 people with advanced cancers (including solid tumors, lymphoma, and myelodysplastic syndromes) that had stopped responding to standard treatments. The main goals were to find a safe dose and check for side effects. Researchers also looked for signs that the drug might control tumor growth.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
JNJ-64619178 (a drug that blocks a protein called PRMT5, which may slow cancer growth)
What this could lead to
If it works, this could point toward a new treatment option for people with advanced cancers that have not responded to other therapies.
What could go wrong
This is a very early Phase 1 trial with only 114 participants, so the drug may not prove effective or safe enough for further testing. Side effects, including serious toxicities, are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell non-Hodgkin lymphoma myelodysplastic syndrome Myelodysplastic Syndromes neoplasm non-Hodgkin lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYELODYSPLASTIC SYNDROMES NEOPLASMS NON-HODGKIN LYMPHOMA SOLID TUMOR, ADULT

Contacts and locations

Locations

  • Carmel Medical Center

    Haifa, 34362, Israel

  • Clinica Univ. de Navarra

    Pamplona, 31008, Spain

  • Florida Specialist and Cancer Institute

    Sarasota, Florida, 34232, United States

  • Goethe Universität Frankfurt

    Frankfurt am Main, 60590, Germany

  • Hadassah Medical Center

    Jerusalem, 9112001, Israel

  • Hosp Clinico Univ de Salamanca

    Salamanca, 37007, Spain

  • Hosp Univ Fund Jimenez Diaz

    Madrid, 28040, Spain

  • Hosp Univ Vall D Hebron

    Barcelona, 08035, Spain

  • Hosp. Univ. Germans Trias I Pujol

    Badalona, 08916, Spain

  • Hosp. Virgen Del Rocio

    Seville, 41013, Spain

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114, United States

  • Ohio State University

    Columbus, Ohio, 43210, United States

  • Princess Margaret Cancer Centre University Health Network

    Toronto, Ontario, M5G1Z5, Canada

  • St. Paul's Hospital

    Vancouver, British Columbia, V6E 1M7, Canada

  • Tel Aviv Sourasky MC

    Tel Aviv, 6423906, Israel

  • Universitaetsklinikum Duesseldorf

    Düsseldorf, 40225, Germany

  • Universitaetsklinikum Leipzig

    Leipzig, 04103, Germany

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.